PRMT5 Inhibitor – BiotechReality – Information Intelligence System for Biopharma

The clinical-stage biotechnology business Suzhou Puhe BioPharma Co., Ltd. and Bayer announced that they have signed a worldwide licensing deal for Puhe BioPharma's oral small molecule PRMT5 inhibitor, which specifically targets tumors with MTAP deletions. The deal grants Bayer the sole global license to create, produce, and market the MTA-cooperative PRMT5 inhibitor. Under the product name BAY 3713372, Bayer has recruited the first subject in a Phase I first-in-human dose escalation study examining an MTA-cooperative PRMT5 inhibitor for the treatment of solid tumors with MTAP deletion. We are looking forward to explore the potential of the PRMT5 inhibitor, which could improve outcomes for patients with MTAP-deleted tumors who often have a poor prognosis, The highly selective targeting of cancer cells while sparing healthy cells, based on the innovative mechanism of action is very promising. This will support our mission to build one of the most transformative and differentiated precision oncology pipelines in the industry. Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer’s Pharmaceuticals Division. We see great potential in MTA-cooperative PRMT5 inhibitors in treating MTAP-deleted tumors. Our MTA-cooperative PRMT5 inhibitor, PH020, now named BAY 3713372, has demonstrated competitive selectivity for PRMT5 bound to MTA and activity in preclinical studies, as well as brain penetration capabilities. We are excited to partner with Bayer, a global leader in the field of life sciences, to advance our PRMT5 inhibitor into the clinic. Together with Bayer, we look forward to bringing this therapeutic option to patients worldwide. Yongqi Guo, CEO of Puhe BioPharma Protein arginine methyltransferase 5 (PRMT5) and a particular gene known as MTAP (metabolic enzyme 5'-deoxy-5'-methylthioadenosine phosphorylase) are essential for cell viability and play significant roles in cell metabolism. Because MTAP deletions, which affect roughly 10 to 30 percent of all cancers, cause tumor cells to produce higher amounts of MTA, BAY 3713372 is made to bind the PRMT5-MTA complex, taking advantage of tumor vulnerability. BAY 3713372 Clinical Trial Since BAY 3713372 is an experimental agent, no health authority has authorized its use for any indication in any nation. For patients with MTAP-deleted solid tumors, this oral, strong selective MTA-cooperative PRMT5 inhibitor is being considered as a possible novel targeted therapeutic approach. Brain penetrance, which enables targeting of primary brain tumors and metastases to the central nervous system (CNS), is one of BAY 3713372's distinctive features. A key player in altering proteins that regulate the cell cycle is protein arginine N-methyltransferase 5 (PRMT5). The methionine salvage route, which recycles methionine from methylthioadenosine (MTA), involves the metabolic enzyme 5'-deoxy-5'-methylthioadenosine phosphorylase (MTAP). This focused strategy exploits the special connection between MTA and PRMT5, resulting in a particular weakness that can be used to treat cancer cells lacking MTAP. Source: Bayer Last Modified:

Tag: PRMT5 Inhibitor

Bayer and Puhe BioPharma With Global License Agreement For Clinical Phase I PRMT5 Inhibitor for Brain Tumors

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment